Dyspnoea severity | Less severe | More severe | Less severe | More severe |
---|---|---|---|---|
Treatment comparison | mMRC score < 2 | mMRC score ≥ 2 | BDI score ≥6 | BDI score <6 |
FEV1 AUC0–3, L | ||||
T/O 5/5 µg – placebo | 0.30*** (0.26, 0.34) | 0.32*** (0.28, 0.36) | 0.32*** (0.29, 0.35) | 0.28*** (0.22, 0.35) |
T/O 5/5 µg – T | 0.11*** (0.07, 0.14) | 0.11*** (0.07, 0.15) | 0.11*** (0.08, 0.14) | 0.10** (0.04, 0.15) |
Trough FEV1, L | ||||
T/O 5/5 µg – placebo | 0.16*** (0.13, 0.20) | 0.16*** (0.13, 0.20) | 0.18*** (0.15, 0.21) | 0.12*** (0.07, 0.18) |
T/O 5/5 µg – T | 0.05* (0.01, 0.08) | 0.02 (−0.01, 0.06) | 0.040** (0.01, 0.07) | 0.01 (−0.04, 0.06) |
SGRQ total score | ||||
T/O 5/5 µg – placebo | −4.20*** (−6.11, −2.29) | −5.11*** (−7.24, −2.97) | −4.78*** (−6.33, −3.23) | −4.38 (−8.95, 0.19) |
T/O 5/5 µg – T | −0.71 (−2.57, 1.16) | −3.44** (−5.47, −1.41) | −1.87* (−3.43, −0.32) | −2.96* (−5.84, −0.09) |
Adjusted mean (95% confidence interval) ***p <0.0001; **p <0.01; *p <0.05